Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double‐blind, randomized controlled trial

Aim To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD. Materials and Methods A double‐blinded, randomized, multicentre study was performed in...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2023-05, Vol.25 (5), p.1174-1185
Main Authors: Lee, Yong‐ho, Kim, Doo‐Man, Yu, Jae Myung, Choi, Kyung Mook, Kim, Sin Gon, Park, Kang Seo, Son, Hyun‐Shik, Chung, Choon Hee, Ahn, Kyu Jeung, Lee, Soon Hee, Song, Ki‐Ho, Kwon, Su Kyoung, Park, Hyeong Kyu, Won, Kyu Chang, Jang, Hak Chul
Format: Article
Language:English
Subjects:
Blood Glucose
Blood Glucose Self-Monitoring
continuous glucose monitoring
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Double-Blind Method
Double-blind studies
DPP‐4 inhibitor
Drug Therapy, Combination
Glucose
Glucose monitoring
glycaemic control
Glycated Hemoglobin
Humans
Hypoglycemic Agents - therapeutic use
Metformin
Metformin - therapeutic use
Protease Inhibitors - therapeutic use
randomized controlled trial
Sitagliptin Phosphate - adverse effects
Statistical analysis
Treatment Outcome
type 2 diabetes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD. Materials and Methods A double‐blinded, randomized, multicentre study was performed in 89 patients with type 2 diabetes treated with metformin alone (6.5% 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14959